Sandra L. Gomez, Colombia
Universidad de La Sabana Infectious Diseases DepartmentPoster Author Of 1 e-Poster
/thumbnails/0.png)
PATIENTS WITH MENINGITIS DUE TO STREPTOCOCCUS PNEUMONIAE ALSO MIGHT DEVELOP MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE)
Author Of 2 Presentations
PATIENTS WITH MENINGITIS DUE TO STREPTOCOCCUS PNEUMONIAE ALSO MIGHT DEVELOP MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) (ID 716)
Abstract
Background
Streptococcus pneumoniae (Spn) is the leading cause of community-acquired pneumonia (CAP) and bacterial meningitis in adults. Recent studies have shown that up to 30% of patients admitted due to pneumococcal CAP develop major adverse cardiovascular events (MACE, i.e., new/worsening arrhythmia, new/worsening heart failure, and myocardial infarction). However, it is unknown whether MACE could also be identified in patients with pneumococcal meningitis.
Methods
In this observational, multicentric retrospective study. We analyzed medical records from adult patients with invasive pneumococcal disease (IPD) reported in a surveillance program across all hospitals in Bogotá, Colombia, between 2012 and 2019. Pneumococcal meningitis was confirmed by the identification of Spn in blood cultures and/or cerebrospinal fluid cultures and clinical presentation. Adverse cardiac outcomes were blinded evaluated in each case.
Results
From a total of 314 patients with microbiological Spn isolation, 19.7% (62/314) were diagnosed with pneumococcal meningitis. Out of the 62 patients evaluated, 10 (16%) developed MACE, 8.1% (5) new/worsening heart failure, 6.5% (4) new/worsening arrhythmia, and 3.2% (2) myocardial infarction.
Conclusions
To our knowledge, this is the first clinical study showing that patients with pneumococcal meningitis could be at risk of MACE as reported in pneumococcal CAP. Further studies are needed to characterize patients at risk better.
A MODEL TO PREDICT THE POTENTIAL ROLE OF NEW ANTI-PNEUMOCOCCAL VACCINES IN BOGOTÁ, COLOMBIA (ID 739)
Abstract
Background
Anti-pneumococcal vaccines are the most effective strategy to prevent pneumococcal disease. However, the pneumococcal burden continues to be a remarkable problem worldwide. Thus, new conjugated vaccines are under development. Through the analysis of the prevalence of pneumococcal serotypes between 2005-2019, we aim to determine the theorical effect of these vaccines in Bogotá, Colombia.
Methods
This is a retrospective analysis of patients reported to a surveillance program due to invasive pneumococcal disease, between 2005 and 2019. We compared the potential serotype coverage of PCV10, PCV13, PCV15, PCV20 by age groups to determine the possible role of these vaccines in Bogotá, Colombia.
Results
A total of 2605 patients were included. In the group of children ˂5 years, PCV10 had serotype coverage of 9%, PCV13 of 27.8%, PCV15 of 28.2%, and PCV20 of 30%. In Adults ˃18 years, PCV10 covered was 11.8%, PCV13 of 26.6%, PCV15 of 27.7%, and PCV20 of 32.7% (Figure-1). Additionally, in adults ˃65 years, PCV10 covered was 10.2%, PCV13 of 26%, PCV15 of 27.4%, and PCV20 of 34%.
Conclusions
According to the most prevalent serotypes in our city, the usage of new vaccines may prevent some episodes of IPD in Bogotá, Colombia. However, further clinical, epidemiological and pharmacoeconomical studies should be performed